Three-Month HIV Prevention Ring Gets EU Backing

Women and adolescent girls at risk of HIV may soon use a ring replaced just four times a year.

Updated on Nov. 21, 2026 in Sexual Health

Bold flat-color editorial illustration of a pale ring beside four evenly spaced stone tokens on a matte surface, in deep red and cream.
The European Medicines Agency has backed a three-month dapivirine HIV prevention ring for women and adolescent girls aged 16 and older, with Kiara Health set to take over its commercial license. AI Illustration. Upload story photo >

Live Poll

Would you consider a longer-lasting HIV prevention option if it were available to you?

The European Medicines Agency has issued a positive scientific opinion for a three-month dapivirine vaginal ring for HIV prevention in women and adolescent girls aged 16 and older, including breastfeeding women. The Population Council will transfer the commercial license for the ring to Kiara Health, a South Africa-based manufacturer.

Why it matters

A ring that stays in place for three months, rather than one, would mean fewer replacements for users who rely on it for ongoing HIV prevention, and the developers project substantially lower annual product costs. The opinion comes after the one-month version of the ring already received regulatory approval in 12 African countries, so this update builds on an existing prevention option rather than introducing a new one.

The regulatory opinion draws on a Phase I crossover trial of 124 women in South Africa, which found the three-month ring well tolerated and delivering higher dapivirine levels than the one-month version. Projected efficacy and cost benefits remain estimates that depend on further evaluation.

The players

European Medicines Agency

The EU regulator that reviews medicines for safety and effectiveness, including antiretroviral products used in HIV prevention.

Population Council

A nonprofit research organization that develops reproductive and sexual health products, including the dapivirine vaginal rings, and is transferring the three-month ring's commercial license.

Kiara Health

A South Africa-based pharmaceutical manufacturer that will take over the commercial license for the three-month dapivirine vaginal ring.

The details

Once inserted into the vagina near the cervix, the ring slowly releases the antiretroviral drug dapivirine at the site of potential infection over three months. Dapivirine works by blocking HIV's ability to make copies of itself inside healthy cells. The three-month design means the ring is replaced four times a year rather than the more frequent schedule required by the one-month version.

Timeline

  1. July 2020: The European Medicines Agency issued a positive scientific opinion for the one-month dapivirine vaginal ring.

  2. November 16, 2026: The Population Council announced the positive EMA opinion for the three-month ring.

Health Landscape

The three-month ring follows the 2020 EMA opinion for the one-month dapivirine ring, which has since been approved in 12 African countries. The new opinion extends that line of prevention products toward less frequent dosing and lower projected costs for ongoing HIV prevention.

If you are a woman or adolescent girl at risk of HIV, a longer-lasting prevention option may eventually reduce how often you need a replacement, and it is worth asking your doctor whether prevention methods like this suit your situation. Availability will depend on regulatory approval and manufacturing in each country, so discuss current options with a clinician or sexual health provider.

The takeaway

A longer-acting HIV prevention ring could mean fewer replacements and lower costs over time, though its full efficacy is still being confirmed. Talk with a sexual health clinician about which prevention options are available to you.

Further reading

For more on how prevention products like this fit into sexual health care, browse our Sexual Health coverage.

Source note: This article includes information reported by The Globe and Mail.

Live Poll

Would you consider a longer-lasting HIV prevention option if it were available to you?